Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
News|Articles|February 3, 2026
6 Endocrinology Headlines You Missed in January 2026
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Catch up with major trial results, key FDA approvals, and more.
Advertisement
Advertisement
During January, endocrinology saw a slew of medical and technological approvals and advancements. The US Food and Drug Administration (FDA) cleared the MiniMed Go Smart Multiple Daily Injection (MDI) app for patients ≥7 years with type 1 diabetes (T1D) or type 2 diabetes (T2D), as well as approving an updated starting dose guideline for inhaled insulin powder in T1D. Diabeloop received clearance for its DBLG2 algorithm and has since partnered with Sequel Med Tech to integrate the program with the Twiist automated insulin delivery system.
Related to this article
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
The 150 mg once-daily pellet formulation gives patients aged ≥ 12 years a capsule alternative for HAE prophylaxis.
FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.
Yoseph Dalia, MD, discusses diagnosing and treating pseudofolliculitis barbae, its occupational impact, and barriers to care in skin of color.
Catch up on any data and key clinician perspectives presented at the Heart Failure Society of America Annual Scientific Meeting 2026.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
Advertisement
Advertisement